Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer

被引：0
|
作者：
Di Huang
Fan Zhang
Haitao Tao
Sujie Zhang
Junxun Ma
Jinliang Wang
Zhefeng Liu
Pengfei Cui
Shixue Chen
Ziwei Huang
Zhaozhen Wu
Lei Zhao
Yi Hu
机构：
[1] Nankai University,School of Medicine
[2] Chinese People’s Liberation Army General Hospital,Department of Medical Oncology
[3] Chinese PLA General Hospital,Department of Graduate Administration
来源：
Targeted Oncology | 2020年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：93 / 100
页数：7
相关论文
共 50 条
  • [1] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
    Huang, Di
    Zhang, Fan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Wang, Jinliang
    Liu, Zhefeng
    Cui, Pengfei
    Chen, Shixue
    Huang, Ziwei
    Wu, Zhaozhen
    Zhao, Lei
    Hu, Yi
    [J]. TARGETED ONCOLOGY, 2020, 15 (01) : 93 - 100
  • [2] Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
    Kim, H.
    Kwon, H. J. K.
    Kim, E. S. K.
    Han, Y. B.
    Lee, J.
    Kim, S. H.
    Kim, Y. J.
    Lee, J.
    Chung, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S470 - S470
  • [3] PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
    Dong, Aoran
    Zhao, Yiming
    Li, Zhihua
    Hu, Hai
    [J]. JOURNAL OF GENE MEDICINE, 2021, 23 (02):
  • [4] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [5] Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
    Kallergi, Galatea
    Vetsika, Eleni-Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Messaritakis, Ippokratis
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [6] A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non-Small Cell Lung Cancer
    Man, J.
    Gebski, V.
    Mulvey, A.
    Hui, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2001 - S2002
  • [7] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [8] Research progression of PD-1/PD-L1 in non-small cell lung cancer
    Xing Liu
    Xiaodong Xie
    [J]. Oncology and Translational Medicine, 2017, 3 (03) : 111 - 115
  • [9] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [10] Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer
    Sheffield, Brandon S.
    Fulton, Regan
    Kalloger, Steve E.
    Milne, Katy
    Geller, Georgia
    Jones, Martin
    Jacquemont, Celine
    Zachara, Susanna
    Zhao, Eric
    Pleasance, Erin
    Laskin, Janessa
    Jones, Steven J. M.
    Marra, Marco A.
    Yip, Stephen
    Nelson, Brad H.
    Gown, Allen M.
    Ho, Cheryl
    Ionescu, Diana N.
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2016, 64 (10) : 587 - 600
12345